Spil Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for SPIL, and when can generic versions of SPIL drugs launch?
SPIL has five approved drugs.
There are four US patents protecting SPIL drugs.
There are nine patent family members on SPIL drugs in seven countries and nine supplementary protection certificates in four countries.
Summary for Spil
| International Patents: | 9 |
| US Patents: | 4 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Spil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-003 | Jan 26, 2018 | RX | Yes | No | 9,700,530 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Spil | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 210838-002 | Apr 16, 2019 | AB2 | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Spil | AMPHOTERICIN B | amphotericin b | INJECTABLE, LIPOSOMAL;INJECTION | 212514-001 | Dec 14, 2021 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-002 | Jan 26, 2018 | RX | Yes | No | 9,700,530 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULES, EXTENDED RELEASE;ORAL | 216018-001 | Feb 28, 2022 | RX | Yes | No | 11,510,878 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Spil Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112017000468 | See Plans and Pricing |
| Australia | 2015287299 | See Plans and Pricing |
| European Patent Office | 3409273 | See Plans and Pricing |
| Japan | 6626492 | See Plans and Pricing |
| European Patent Office | 3166599 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Spil Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1109558 | 2008/034 | Ireland | See Plans and Pricing | PRODUCT NAME: RANOLAZINE OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/08/462/001 20080709 |
| 1411900 | 2011/016 | Ireland | See Plans and Pricing | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| 1109558 | SPC/GB08/058 | United Kingdom | See Plans and Pricing | PRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/08/462/001 20080714; UK EU/1/08/462/002 20080714; UK EU/1/08/462/003 20080714; UK EU/1/08/462/004 20080714; UK EU/1/08/462/005 20080714; UK EU/1/08/462/006 20080714 |
| 0124495 | SPC/GB01/006 | United Kingdom | See Plans and Pricing | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| 1411900 | 2011C/016 | Belgium | See Plans and Pricing | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
